Modulating Early-life Nutrition for Childhood Obesity Prevention
NutrOb
1 other identifier
interventional
50
1 country
1
Brief Summary
In this study, betaine intake will be increased in formula-fed infants through formula milk supplementation. To do this, a double-blind randomized study has been designed with the supplementation group (infant formula supplemented with betaine) and control group (unsupplemented infant formula). The main objectives of the study are to determine the safety of supplementation and to assess whether there are changes in infant growth.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 13, 2023
CompletedFirst Posted
Study publicly available on registry
October 19, 2023
CompletedStudy Start
First participant enrolled
October 31, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
March 20, 2026
March 1, 2026
2.6 years
October 13, 2023
March 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in weight-for-length z score
Weight and length will be measured at different time-points and combined to calculate weight-for-length z scores.
From start to the end of treatment at 12 weeks and at 12 months of follow-up
Changes in fecal microbiota composition
Differences in features associated with a healthy mucosal layer and metabolic state (e.g. Bifidobacteria and Akkermansia relative amount). Stool samples will be processed to isolate the bacterial DNA. Microbiome composition will be determined by DNA sequencing.
At 4 weeks and 12 weeks end of treatment, and at 12 months of follow-up
Secondary Outcomes (2)
Infant body composition
At 12 months of follow-up
Urine one-carbon metabolite concentration
At 4 weeks and 12 weeks after start of treatment
Other Outcomes (1)
Infant's DNA methylome
At the end of the 12-week treatment
Study Arms (2)
Control group
SHAM COMPARATORUse of unmodified infant formula for 12 weeks
Betaine supplementation group
EXPERIMENTALUse of infant formula supplemented with betaine (final concentration of 100 µmol/L) for 12 weeks
Interventions
Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.
Regular (unmodified) infant formula . The intervention will last for 12 weeks.
Eligibility Criteria
You may qualify if:
- Maternal age between 17 and 42 years
- Maternal pre-pregnancy BMI equal or higher than 25
- Gestational age at birth \> 37 weeks
- No exclusive breastfeeding at time of recruitment
You may not qualify if:
- Presence of disease or malformations in the infant
- Infant birth weight \< -1 SD (standard deviations)
- Multiple pregnancy
- Elective c-section
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Sant Joan de Déu
Barcelona, Barcelona, 08950, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 13, 2023
First Posted
October 19, 2023
Study Start
October 31, 2023
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
March 20, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share